<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> (AF) is the most common sustained <z:hpo ids='HP_0011675'>cardiac arrhythmia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is associated with significant morbidity and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>At the societal level, AF carries an enormous cost </plain></SENT>
<SENT sid="3" pm="."><plain>Strategies aimed at reducing AF morbidity and mortality and containing the associated fiscal burden are of paramount importance </plain></SENT>
<SENT sid="4" pm="."><plain>This review will discuss AF treatment strategies and economics, focusing on the impact of <z:chebi fb="0" ids="50659">dronedarone</z:chebi>, a novel antiarrhythmic agent </plain></SENT>
</text></document>